Gossamer Bio Extends Debt Exchange Deadline, Reports $181M Tendered
GOSS sits 25% above its 52-week low of $0.163 on elevated volume (1.8× avg).
Summary
Gossamer Bio extended the early tender deadline for its distressed debt exchange and reported that $181 million of its convertible notes have been tendered, moving closer to the required 98% for the critical restructuring.
Key Events · Financing and Capital Events · GOSS
-
Debt Exchange Deadline Extended
The early tender deadline for the exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027 has been extended to June 2, 2026.
-
Significant Tender Progress
As of June 1, 2026, $181,052,000 in aggregate principal amount of Existing Convertible Notes has been validly tendered, representing over 90% of the notes.
-
Critical Condition for Exchange
The exchange offer requires a minimum of 98% of the aggregate principal amount of Existing Convertible Notes to be validly tendered.
-
Expected Early Settlement Date
The early settlement date, if conditions are met, is now expected to occur on June 4, 2026.
Analysis · GOSS · Life Sciences
This 8-K provides a critical update on Gossamer Bio's distressed debt exchange, which is essential for the company's financial viability. The extension of the early tender deadline and the disclosure that $181 million of the $200 million convertible notes have been tendered indicate significant progress towards meeting the 98% tender condition. Successfully completing this exchange is crucial for the company, which is facing a going concern warning and a Nasdaq delisting notice.
At the time of this filing, GOSS was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.5M. The 52-week trading range was $0.16 to $3.87. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.